Logo image of NICE

NICE LTD - SPON ADR (NICE) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:NICE - US6536561086 - ADR

117.22 USD
-0.52 (-0.44%)
Last: 1/7/2026, 8:00:01 PM
117.22 USD
0 (0%)
After Hours: 1/7/2026, 8:00:01 PM
Fundamental Rating

6

NICE gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 276 industry peers in the Software industry. NICE scores excellent on profitability, but there are some minor concerns on its financial health. NICE scores decently on growth, while it is valued quite cheap. This could make an interesting combination. These ratings could make NICE a good candidate for value investing.


Dividend Valuation Growth Profitability Health

8

1. Profitability

1.1 Basic Checks

NICE had positive earnings in the past year.
In the past year NICE had a positive cash flow from operations.
Each year in the past 5 years NICE has been profitable.
In the past 5 years NICE always reported a positive cash flow from operatings.
NICE Yearly Net Income VS EBIT VS OCF VS FCFNICE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

1.2 Ratios

NICE has a better Return On Assets (10.83%) than 85.87% of its industry peers.
The Return On Equity of NICE (14.45%) is better than 80.80% of its industry peers.
NICE's Return On Invested Capital of 11.19% is amongst the best of the industry. NICE outperforms 86.96% of its industry peers.
NICE had an Average Return On Invested Capital over the past 3 years of 8.49%. This is below the industry average of 10.78%.
The 3 year average ROIC (8.49%) for NICE is below the current ROIC(11.19%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 10.83%
ROE 14.45%
ROIC 11.19%
ROA(3y)6.78%
ROA(5y)5.84%
ROE(3y)10.34%
ROE(5y)9.15%
ROIC(3y)8.49%
ROIC(5y)7.35%
NICE Yearly ROA, ROE, ROICNICE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2 4 6 8 10

1.3 Margins

NICE's Profit Margin of 19.37% is amongst the best of the industry. NICE outperforms 81.88% of its industry peers.
NICE's Profit Margin has improved in the last couple of years.
With an excellent Operating Margin value of 22.02%, NICE belongs to the best of the industry, outperforming 88.04% of the companies in the same industry.
In the last couple of years the Operating Margin of NICE has grown nicely.
NICE has a Gross Margin (67.05%) which is in line with its industry peers.
NICE's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 22.02%
PM (TTM) 19.37%
GM 67.05%
OM growth 3Y13.23%
OM growth 5Y5.7%
PM growth 3Y15.65%
PM growth 5Y6.35%
GM growth 3Y-0.37%
GM growth 5Y0.16%
NICE Yearly Profit, Operating, Gross MarginsNICE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60

5

2. Health

2.1 Basic Checks

NICE has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
Compared to 1 year ago, NICE has more shares outstanding
NICE has more shares outstanding than it did 5 years ago.
NICE has a better debt/assets ratio than last year.
NICE Yearly Shares OutstandingNICE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
NICE Yearly Total Debt VS Total AssetsNICE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B 5B

2.2 Solvency

NICE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z N/A
ROIC/WACC1.3
WACC8.58%
NICE Yearly LT Debt VS Equity VS FCFNICE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

2.3 Liquidity

A Current Ratio of 1.41 indicates that NICE should not have too much problems paying its short term obligations.
With a Current ratio value of 1.41, NICE perfoms like the industry average, outperforming 43.84% of the companies in the same industry.
A Quick Ratio of 1.41 indicates that NICE should not have too much problems paying its short term obligations.
NICE has a Quick ratio (1.41) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 1.41
Quick Ratio 1.41
NICE Yearly Current Assets VS Current LiabilitesNICE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B 2.5B

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 15.49% over the past year.
NICE shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 15.93% yearly.
The Revenue has grown by 9.24% in the past year. This is quite good.
The Revenue has been growing by 11.69% on average over the past years. This is quite good.
EPS 1Y (TTM)15.49%
EPS 3Y19.48%
EPS 5Y15.93%
EPS Q2Q%10.42%
Revenue 1Y (TTM)9.24%
Revenue growth 3Y12.5%
Revenue growth 5Y11.69%
Sales Q2Q%6.09%

3.2 Future

The Earnings Per Share is expected to grow by 5.06% on average over the next years.
Based on estimates for the next years, NICE will show a quite strong growth in Revenue. The Revenue will grow by 8.47% on average per year.
EPS Next Y12.5%
EPS Next 2Y2.42%
EPS Next 3Y5.06%
EPS Next 5YN/A
Revenue Next Year7.61%
Revenue Next 2Y7.84%
Revenue Next 3Y8.47%
Revenue Next 5YN/A

3.3 Evolution

The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
NICE Yearly Revenue VS EstimatesNICE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 1B 2B 3B
NICE Yearly EPS VS EstimatesNICE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2 4 6 8 10

9

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 9.48, the valuation of NICE can be described as reasonable.
NICE's Price/Earnings ratio is rather cheap when compared to the industry. NICE is cheaper than 88.41% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 26.92, NICE is valued rather cheaply.
The Price/Forward Earnings ratio is 9.82, which indicates a very decent valuation of NICE.
88.04% of the companies in the same industry are more expensive than NICE, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.57, NICE is valued rather cheaply.
Industry RankSector Rank
PE 9.48
Fwd PE 9.82
NICE Price Earnings VS Forward Price EarningsNICE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, NICE is valued cheaper than 91.67% of the companies in the same industry.
92.03% of the companies in the same industry are more expensive than NICE, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 10.46
EV/EBITDA 8.26
NICE Per share dataNICE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 20 40 60

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The excellent profitability rating of NICE may justify a higher PE ratio.
PEG (NY)0.76
PEG (5Y)0.6
EPS Next 2Y2.42%
EPS Next 3Y5.06%

0

5. Dividend

5.1 Amount

NICE does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

NICE LTD - SPON ADR

NASDAQ:NICE (1/7/2026, 8:00:01 PM)

After market: 117.22 0 (0%)

117.22

-0.52 (-0.44%)

Chartmill FA Rating
GICS IndustryGroupSoftware & Services
GICS IndustrySoftware
Earnings (Last)11-13 2025-11-13/dmh
Earnings (Next)02-13 2026-02-13/bmo
Inst Owners12.79%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap7.24B
Revenue(TTM)2.88B
Net Income(TTM)557.97M
Analysts80
Price Target200.3 (70.88%)
Short Float %2.75%
Short Ratio2
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-1.64%
Min EPS beat(2)-1.87%
Max EPS beat(2)-1.41%
EPS beat(4)0
Avg EPS beat(4)-1.13%
Min EPS beat(4)-1.87%
Max EPS beat(4)-0.07%
EPS beat(8)4
Avg EPS beat(8)0.76%
EPS beat(12)8
Avg EPS beat(12)1.33%
EPS beat(16)11
Avg EPS beat(16)1.39%
Revenue beat(2)0
Avg Revenue beat(2)-0.81%
Min Revenue beat(2)-1.48%
Max Revenue beat(2)-0.14%
Revenue beat(4)0
Avg Revenue beat(4)-1.21%
Min Revenue beat(4)-1.97%
Max Revenue beat(4)-0.14%
Revenue beat(8)0
Avg Revenue beat(8)-1.28%
Revenue beat(12)0
Avg Revenue beat(12)-1.29%
Revenue beat(16)2
Avg Revenue beat(16)-0.83%
PT rev (1m)-6.28%
PT rev (3m)5.92%
EPS NQ rev (1m)-0.08%
EPS NQ rev (3m)-5.57%
EPS NY rev (1m)-0.08%
EPS NY rev (3m)-1.59%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.88%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.33%
Valuation
Industry RankSector Rank
PE 9.48
Fwd PE 9.82
P/S 2.51
P/FCF 10.46
P/OCF 9.2
P/B 1.87
P/tB 9.07
EV/EBITDA 8.26
EPS(TTM)12.36
EY10.54%
EPS(NY)11.93
Fwd EY10.18%
FCF(TTM)11.21
FCFY9.56%
OCF(TTM)12.74
OCFY10.87%
SpS46.65
BVpS62.53
TBVpS12.93
PEG (NY)0.76
PEG (5Y)0.6
Graham Number131.87
Profitability
Industry RankSector Rank
ROA 10.83%
ROE 14.45%
ROCE 15.21%
ROIC 11.19%
ROICexc 12.56%
ROICexgc 71.45%
OM 22.02%
PM (TTM) 19.37%
GM 67.05%
FCFM 24.02%
ROA(3y)6.78%
ROA(5y)5.84%
ROE(3y)10.34%
ROE(5y)9.15%
ROIC(3y)8.49%
ROIC(5y)7.35%
ROICexc(3y)14.21%
ROICexc(5y)12.54%
ROICexgc(3y)163.28%
ROICexgc(5y)N/A
ROCE(3y)11.55%
ROCE(5y)10%
ROICexgc growth 3Y25.64%
ROICexgc growth 5Y53.44%
ROICexc growth 3Y23.73%
ROICexc growth 5Y18.38%
OM growth 3Y13.23%
OM growth 5Y5.7%
PM growth 3Y15.65%
PM growth 5Y6.35%
GM growth 3Y-0.37%
GM growth 5Y0.16%
F-Score8
Asset Turnover0.56
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 50.85%
Cap/Sales 3.28%
Interest Coverage 250
Cash Conversion 95.89%
Profit Quality 124.01%
Current Ratio 1.41
Quick Ratio 1.41
Altman-Z N/A
F-Score8
WACC8.58%
ROIC/WACC1.3
Cap/Depr(3y)48.45%
Cap/Depr(5y)43.32%
Cap/Sales(3y)3.65%
Cap/Sales(5y)3.66%
Profit Quality(3y)152.88%
Profit Quality(5y)173.68%
High Growth Momentum
Growth
EPS 1Y (TTM)15.49%
EPS 3Y19.48%
EPS 5Y15.93%
EPS Q2Q%10.42%
EPS Next Y12.5%
EPS Next 2Y2.42%
EPS Next 3Y5.06%
EPS Next 5YN/A
Revenue 1Y (TTM)9.24%
Revenue growth 3Y12.5%
Revenue growth 5Y11.69%
Sales Q2Q%6.09%
Revenue Next Year7.61%
Revenue Next 2Y7.84%
Revenue Next 3Y8.47%
Revenue Next 5YN/A
EBIT growth 1Y20%
EBIT growth 3Y27.38%
EBIT growth 5Y18.06%
EBIT Next Year19.23%
EBIT Next 3Y5.28%
EBIT Next 5YN/A
FCF growth 1Y47.34%
FCF growth 3Y22.92%
FCF growth 5Y18.61%
OCF growth 1Y41.03%
OCF growth 3Y21.71%
OCF growth 5Y17.35%

NICE LTD - SPON ADR / NICE FAQ

What is the ChartMill fundamental rating of NICE LTD - SPON ADR (NICE) stock?

ChartMill assigns a fundamental rating of 6 / 10 to NICE.


Can you provide the valuation status for NICE LTD - SPON ADR?

ChartMill assigns a valuation rating of 9 / 10 to NICE LTD - SPON ADR (NICE). This can be considered as Undervalued.


Can you provide the profitability details for NICE LTD - SPON ADR?

NICE LTD - SPON ADR (NICE) has a profitability rating of 8 / 10.


Can you provide the PE and PB ratios for NICE stock?

The Price/Earnings (PE) ratio for NICE LTD - SPON ADR (NICE) is 9.48 and the Price/Book (PB) ratio is 1.87.


What is the financial health of NICE LTD - SPON ADR (NICE) stock?

The financial health rating of NICE LTD - SPON ADR (NICE) is 5 / 10.